Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 24;34(12):1371–1381. doi: 10.1177/0269881120965880

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 4. — Effects of scopolamine microinfusions into the mediodorsal (MD) and the anterior thalamus (AT) on five-choice serial reaction time task (5-CSRTT) performance. No significant effect was produced in (a) the number of trials or (b) accuracy of responses. (c) The percentage of omitted responses was similarly unaffected in either region by all doses. These results support a lack of effect on sustained attention by muscarinic agonism in the MD and AT. (d) The percentage premature responses were also left unaffected, with similar results for (e) the ratio of perseverative responses:correct responses, indicating that scopolamine did not alter aspects of inhibitory control. (f) There was no effect on reward collection latency. (g) Scopolamine infusions produced a main effect of dose on correct response latency, but no significant interaction of dose × region was seen. (h) Incorrect response latencies were unaffected by infusions into either thalamic region. Significant main effect of dose-only is denoted as p<0.005.